Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version

Krisztina Horváth, Zsuzsanna Aschermann, Péter Ács, Gabriella Deli, J. Janszky, S. Komoly, Kázmér Karádi, Márton Kovács, Attila Makkos, Béla Faludi, N. Kovács

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity- and specificity-based method by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than -3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and -0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of -3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.

Original languageEnglish
Article number970534
JournalParkinson's Disease
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Parkinson Disease
Sleep
ROC Curve
Dementia
Outcome Assessment (Health Care)
Minimal Clinically Important Difference
Sensitivity and Specificity
Population

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version. / Horváth, Krisztina; Aschermann, Zsuzsanna; Ács, Péter; Deli, Gabriella; Janszky, J.; Komoly, S.; Karádi, Kázmér; Kovács, Márton; Makkos, Attila; Faludi, Béla; Kovács, N.

In: Parkinson's Disease, Vol. 2015, 970534, 2015.

Research output: Contribution to journalArticle

Horváth, K, Aschermann, Z, Ács, P, Deli, G, Janszky, J, Komoly, S, Karádi, K, Kovács, M, Makkos, A, Faludi, B & Kovács, N 2015, 'Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version', Parkinson's Disease, vol. 2015, 970534. https://doi.org/10.1155/2015/970534
Horváth, Krisztina ; Aschermann, Zsuzsanna ; Ács, Péter ; Deli, Gabriella ; Janszky, J. ; Komoly, S. ; Karádi, Kázmér ; Kovács, Márton ; Makkos, Attila ; Faludi, Béla ; Kovács, N. / Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version. In: Parkinson's Disease. 2015 ; Vol. 2015.
@article{3ee4ac8b7617455eb03691c0e573b9da,
title = "Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version",
abstract = "Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity- and specificity-based method by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than -3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and -0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of -3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.",
author = "Krisztina Horv{\'a}th and Zsuzsanna Aschermann and P{\'e}ter {\'A}cs and Gabriella Deli and J. Janszky and S. Komoly and K{\'a}zm{\'e}r Kar{\'a}di and M{\'a}rton Kov{\'a}cs and Attila Makkos and B{\'e}la Faludi and N. Kov{\'a}cs",
year = "2015",
doi = "10.1155/2015/970534",
language = "English",
volume = "2015",
journal = "Parkinson's Disease",
issn = "2090-8083",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version

AU - Horváth, Krisztina

AU - Aschermann, Zsuzsanna

AU - Ács, Péter

AU - Deli, Gabriella

AU - Janszky, J.

AU - Komoly, S.

AU - Karádi, Kázmér

AU - Kovács, Márton

AU - Makkos, Attila

AU - Faludi, Béla

AU - Kovács, N.

PY - 2015

Y1 - 2015

N2 - Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity- and specificity-based method by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than -3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and -0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of -3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.

AB - Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity- and specificity-based method by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than -3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and -0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of -3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.

UR - http://www.scopus.com/inward/record.url?scp=84946034526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946034526&partnerID=8YFLogxK

U2 - 10.1155/2015/970534

DO - 10.1155/2015/970534

M3 - Article

VL - 2015

JO - Parkinson's Disease

JF - Parkinson's Disease

SN - 2090-8083

M1 - 970534

ER -